<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464033</url>
  </required_header>
  <id_info>
    <org_study_id>EDCR IIa</org_study_id>
    <nct_id>NCT02464033</nct_id>
  </id_info>
  <brief_title>EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes</brief_title>
  <official_title>Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd®), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnny Ludvigsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Child Diabetes Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ostergotland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diamyd Medical AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study is to:

        -  Evaluate the tolerability of a combination therapy with Diamyd, vitamin D and etanercept

        -  Evaluate how the above mentioned treatments influence the immune system and endogenous
           insulin secretion
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactions of the injection site as an assessment of the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)</measure>
    <time_frame>6 months</time_frame>
    <description>Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Evaluate the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of infection as an assessment of the tolerability of a combination therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events and number of participants with adverse events as an assessment of the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of adverse events and number of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of serious adverse events and number of participants with serious adverse events as an assessment of the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of serious adverse events and number of participants with serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examinations, including neurological assessments as an assessment of the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)</measure>
    <time_frame>6 months</time_frame>
    <description>Physical examinations, including neurological assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory measurements as an assessment of the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)</measure>
    <time_frame>6 months</time_frame>
    <description>Laboratory measurements (biochemistry and haematology), including Calcium and Vitamin D in serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GAD65AB titer measured to Evaluate the tolerability of a combination therapy with Diamyd, Vitamin D and etanercept at Month 6 (main study Period)</measure>
    <time_frame>6 months</time_frame>
    <description>GAD65AB titer (GADA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in immune system markers from baseline to Month 6 (main study period) and subsequent visits during the extension study period</measure>
    <time_frame>6 months, 9, 15 and 30 months</time_frame>
    <description>Inflammatory markers, (e.g. TNF-alfa, IL-1 beta, IL-2, IL-17); Th2-deviation of cell-mediated immune response seen e.g. as increased ratio IL-5,10, 13 in comparison with IFN-gamma, TNF-alfa, IL-1 beta and IL-17; Regulatory T-cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide: Area Under the Curve (mean 0-120 min) during an MMTT, change from baseline</measure>
    <time_frame>6 months, 9, 15 and 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a stimulated maximum C-peptide level above 0.2 nmol/L</measure>
    <time_frame>6 months, 9, 15 and 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c (HbA1c), change from baseline</measure>
    <time_frame>6 months, 9, 15 and 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exogenous insulin dose per kg body weight and 24 hours, change from baseline</measure>
    <time_frame>6 months, 9, 15 and 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide: Fasting, 90 minute value, change from baseline</measure>
    <time_frame>6 months, 9, 15 and 30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GAD-Alum</intervention_name>
    <arm_group_label>A</arm_group_label>
    <other_name>Diamyd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent given by patients and parent(s)/legal guardian(s)

          2. Type 1 diabetes according to the ADA classification, diagnosed within the previous 100
             days at the time of screening

          3. Age 8.00 -17.99 years at time of screening

          4. Fasting C-peptide at time of screening ≥0.12 nmol/L

          5. Positive for GADA but &lt; 50 000 Units

          6. Menarchal females must agree to avoid pregnancy and have a negative urine pregnancy
             test

          7. Immunity against Varicella, either through previous infection or vaccination

          8. Patients must follow the Swedish vaccination programme

          9. Patients of childbearing potential must agree to using adequate contraception, if
             sexually active, until 1 year after the last administration of GAD-alum and
             etanercept. Adequate contraception is as follows:

        For females of childbearing potential:

          1. oral (except low-dose gestagen (lynestrenol and norestisteron), injectable, or
             implanted hormonal contraceptives (females)

          2. intrauterine device (females)

          3. intrauterine system (for example, progestin-releasing coil) (females)

          4. vasectomized male (with appropriate postvasectomy documentation of the absence of
             sperm in the ejaculate)

        For males of childbearing potential:

        a. Condom (male)

        Exclusion Criteria:

          1. Previous or current treatment with immunosuppressant therapy (although topical or
             inhaled steroids are accepted)

          2. Continuous treatment with anti-inflammatory drug (sporadic treatment e.g. because of
             headache or in connection with fever a few days will be accepted)

          3. Treatment with any oral or injected anti-diabetic medications (especially hypoglycemic
             agents) other than insulin

          4. Treatment with Vitamin D, marketed or not, or unwilling to abstain from such
             medication during the trial

          5. A history of hypercalcemia

          6. A history of anaemia or significantly abnormal haematology results at screening

          7. A history of epilepsy, head trauma or cerebro-vascular accident, or clinical features
             of continuous motor unit activity in proximal muscles

          8. Clinically significant history of acute reaction to vaccines or other drugs in the
             past

          9. Treatment with any vaccine within 4 months prior to planned first administration of
             GAD-Alum or planned treatment with vaccine up to 4 months after the last injection
             with GAD-Alum, including influenza vaccine

         10. Participation in other clinical trials with a new chemical entity within the previous
             3 months

         11. Inability or unwillingness to comply with the provisions of this protocol

         12. A history of alcohol or drug abuse

         13. A significant illness other than diabetes within 2 weeks prior to first dosing

         14. Known human immunodeficiency virus (HIV)

         15. Prior or active viral hepatitis B or C infection

         16. Females who are lactating or pregnant (for females who have started menstruating the
             possibility of pregnancy must be excluded by urine βHCG on-site within 24 hours prior
             to the GAD-Alum and etanercept administration, respectively)

         17. Males or females not willing to use adequate contraception, if sexually active, until
             1 year after the last GAD-Alum and etanercept administration, respectively

         18. Presence of associated serious disease or condition, including active skin infections
             that preclude subcutaneous injection, which in the opinion of the investigator makes
             the patient non-eligible for the study.

         19. Deemed by the investigator not being able to follow instructions and/or follow the
             study protocol

         20. Active infection, including chronic and local infection or a history of previous
             tendency to serious infections, recent or ongoing uncontrolled bacterial, viral,
             fungal or other opportunistic infections, or known infection with active EBV or CMV

         21. Hypersensivity to the active substance in Enbrel (etanercept) or other ingredients in
             Enbrel

         22. Active or inactive (latent) tuberculosis (TBC) at screening

         23. History of malignancy or significant cardiovascular disease

         24. Current or history of leukopenia, anemia and/or thrombocytopeni

         25. Liver disease (clinical or hepatic enzymes &gt;3 times the upper limit of normal (ULN))

         26. Renal insufficiency (clinical or creatinine &gt;3 times the upper limit of normal (ULN))

         27. MS, undefined neurologic condition or known SLE, or anti-nuclear or known
             doublestranded DNA antibody positivity

         28. Arrhythmia

         29. Pancreatitis

         30. Vitamin D serum levels &gt;100 nmol/L at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnny Ludvigsson, MD,PhD,Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linkoeping University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital, UMAS</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sachsska, Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uddevalla Hospital</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Västerås Hospital</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Johnny Ludvigsson</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>Diamyd</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Juvenile Diabetes</keyword>
  <keyword>Diabetes Type 1</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Autoimmune Diabetes</keyword>
  <keyword>Insulin Dependent Diabetes</keyword>
  <keyword>Type 1 Diabetes MellitusType 1 Diabetes Mellitus</keyword>
  <keyword>rhGAD65</keyword>
  <keyword>GAD65</keyword>
  <keyword>GAD-Alum</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes mellitus Type 1</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Etanercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

